4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Consensus Recommendation of “Moderate Buy” by Brokerages

by · The Cerbat Gem

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the ten brokerages that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and eight have issued a buy recommendation on the company. The average 12-month price target among analysts that have covered the stock in the last year is $33.25.

Several analysts have weighed in on FDMT shares. Leerink Partners reiterated an “outperform” rating and issued a $17.00 price objective on shares of 4D Molecular Therapeutics in a research note on Friday, October 31st. Royal Bank Of Canada reiterated an “outperform” rating on shares of 4D Molecular Therapeutics in a research report on Wednesday, January 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Wednesday, October 8th. Barclays lowered their price objective on 4D Molecular Therapeutics from $38.00 to $33.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 11th. Finally, Wall Street Zen downgraded 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 6th.

Get Our Latest Stock Analysis on FDMT

4D Molecular Therapeutics Stock Performance

Shares of FDMT stock traded down $0.06 during midday trading on Friday, hitting $7.55. 754,442 shares of the company were exchanged, compared to its average volume of 942,831. The firm’s 50 day moving average price is $9.45 and its two-hundred day moving average price is $8.03. The firm has a market capitalization of $431.33 million, a P/E ratio of -2.01 and a beta of 2.99. 4D Molecular Therapeutics has a 52 week low of $2.23 and a 52 week high of $12.34.

4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report) last released its quarterly earnings results on Monday, November 10th. The company reported ($1.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.02) by $0.01. 4D Molecular Therapeutics had a negative return on equity of 47.27% and a negative net margin of 174,314.17%.The business had revenue of $0.09 million during the quarter, compared to the consensus estimate of $0.40 million. Analysts expect that 4D Molecular Therapeutics will post -2.84 EPS for the current year.

Insider Transactions at 4D Molecular Therapeutics

In other 4D Molecular Therapeutics news, insider Scott Bizily sold 2,678 shares of the stock in a transaction dated Friday, October 24th. The shares were sold at an average price of $12.00, for a total transaction of $32,136.00. Following the sale, the insider directly owned 3,594 shares in the company, valued at $43,128. This represents a 42.70% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders have sold 6,337 shares of company stock worth $70,649 in the last 90 days. Corporate insiders own 9.60% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Dynamic Technology Lab Private Ltd bought a new stake in 4D Molecular Therapeutics during the first quarter worth $39,000. Wexford Capital LP bought a new position in 4D Molecular Therapeutics in the third quarter valued at about $41,000. Los Angeles Capital Management LLC bought a new position in 4D Molecular Therapeutics in the second quarter valued at about $42,000. Quadrature Capital Ltd acquired a new position in 4D Molecular Therapeutics during the second quarter worth about $42,000. Finally, Farther Finance Advisors LLC lifted its holdings in shares of 4D Molecular Therapeutics by 117.4% in the third quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company’s stock worth $43,000 after acquiring an additional 2,674 shares during the last quarter. 99.27% of the stock is owned by institutional investors.

4D Molecular Therapeutics Company Profile

(Get Free Report)

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.

Featured Articles